Drug Combination Screening Services

Combination therapies have emerged as the standard of care in many diseases including oncology. It is widely accepted that the biological pathways fundamental in many serious diseases are highly complex with individual cell types containing a unique network of pathways and, as a result, traditional monotherapies are often insufficient.

With a decade of experience analysing over 10 million unique drug combinations, we are recognized as the leader in drug combination screening. Partner with us and gain access to our deep combination screening expertise, proprietary HT combination drug screening platform and Chalice™ bioinformatics software to discover new combination therapies and aid patient stratification.

Horizon’s Combination Drug Screening Platform

How Can Horizon’s Combination Drug Screening Platform Work for You?

  • Study combination drug responses to identify synergistic and antagonistic interactions
  • Compare drug activity with approved and emerging therapies
  • Access over 800 highly characterised cell lines to rationalise patient stratification decisions for your drug candidate
  • Ability to study small molecules, antibodies, and antibody drug conjugates
How the Platform Works

We have spent more than a decade designing and refining our automated platform and proprietary Chalice software. With our platform you can profile your compounds as single agents or combinations across hundreds of well annotated cancer cell lines, and gain actionable insights in a short period of time.

Our HT combination screening platform operates by using sophisticated bioinformatics tools, which can assess drug or compound combinations over a defined range to look for synergistic or antagonistic effects. These may be observed either as an increase in the anti-proliferative or cell killing effect, or as potency shift such that lower dosages are required to see the same therapeutic effect.

Combination effects can manifest as efficacy boosts (orange line) or potency shifts (blue line)
Enhancer Screening Diagram

Once the effect of each compound as a single agent is removed, an Excess Matrix is generated that provides a simple visual representation of information about combination activity at the multiple concentrations and ratios of the two drugs and where synergies or antagonism can be seen.

Watching our recent webinar to learn more about our drug combination screening platform.

Drug combination screening

Our Cell Line Collection

  • Over 800 cell lines; 90% of which overlap with Cancer Cell Line Encyclopaedia (CCLE)
  • Cell lines are characterized for their suitability for HTS work including seeding densities and assay conditions to generate quality data
  • Cell lines are grown in vendor-recommended media
  • X-MAN® isogenic mutant and wild type cell pairs are also available for screening
 Cancer cell lines

Why Work with Horizon Discovery?

  • Over 10 years of experience in analysing over 10 million unique drug combinations
  • Cost-effective screening platform that delivers actionable insights in a short period of time
  • Experience in screening of small molecules, biologics and ADCs
  • Oncology focused compound library of over 250 approved drugs, emerging therapeutics and molecular probes
  • Customized treatment times and dosing regiments to more closely mirror in vivo studies
  • Proprietary Chalice™ software allows easy analysis and visualization of data
  • We are committed to the success of your project, working closely with you from project design through interpretation of the results

Contact us to discuss your project

Related Materials:

ATL313, A Potent, and Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple MyelomaPoster
Identification of Combinatorial Drugs that Synergistically Kill Both Eribulin-Sensitive and Eribulin-Insensitive Tumor CellsPaper
Pharmacogenomic Investigation of Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765): Drug Sensitivity in Diffuse Large B-Cell Lymphoma (DLBCL) Within a Tumor Microenvironment–Aligned High-Throughput ScreenPoster

Read more...

Back to top